about
Occlusion regulates epidermal cytokine production and inhibits scar formationAttenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive ratsElevated levels of matrix metalloprotein-3 in patients with coronary aneurysm: A case control studySecond-hand smoke-induced cardiac fibrosis is related to the Fas death receptor apoptotic pathway without mitochondria-dependent pathway involvement in rats.Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative DiseasesProgression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expressionVasomotor effects of L- and D-arginine in stenotic atheromatous coronary plaqueANG II increases TIMP-1 expression in rat aortic smooth muscle cells in vivoCatalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domainDiagnostic approaches for diabetic cardiomyopathy.Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy.Role of MMPs and plasminogen activators in angiogenesis after transmyocardial laser revascularization in dogs.Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.Cholesterol lowering and coronary artery disease: mechanisms of risk reduction.Inhibitory effects of lithospermic acid on proliferation and migration of rat vascular smooth muscle cells.Matrix metalloproteinase 2 inhibition: combined quantum mechanics and molecular mechanics studies of the inhibition mechanism of (4-phenoxyphenylsulfonyl)methylthiirane and its oxirane analogue.Matrix metalloproteinase 2 (MMP2) inhibition: DFT and QM/MM studies of the deprotonation-initialized ring-opening reaction of the sulfoxide analogue of SB-3CT.Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications.Transgenic mouse models in angiogenesis and cardiovascular disease.AP-1 (Fra-1/c-Jun)-mediated induction of expression of matrix metalloproteinase-2 is required for 15S-hydroxyeicosatetraenoic acid-induced angiogenesis.Changing concepts of atherogenesis.Blockade of TGF-β by catheter-based local intravascular gene delivery does not alter the in-stent neointimal response, but enhances inflammation in pig coronary arteries.Lipophilic calcium antagonists in antiatherosclerotic therapy.Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms.QM/MM Studies of the Matrix Metalloproteinase 2 (MMP2) Inhibition Mechanism of (S)-SB-3CT and its Oxirane Analogue.Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease.Transforming growth factor-β1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF-κB pathways.Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice.Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium.Pharmacogenetics of Lipid-lowering Therapies.Post-stenotic aortic dilatation.Matrix metalloproteinases and atherosclerotic plaque instability.Biomarkers to improve diagnosis and monitoring of obstructive sleep apnea syndrome: current status and future perspectives.Expression of matrix metalloproteinase-12 in aortic dissectionArterial stiffness: a brief review.Beyond blood pressure: the endothelium and atherosclerosis progression.The role of matrix metalloproteinases in vascular disease.Pipoxolan ameliorates cerebral ischemia via inhibition of neuronal apoptosis and intimal hyperplasia through attenuation of VSMC migration and modulation of matrix metalloproteinase-2/9 and Ras/MEK/ERK signaling pathwaysGene expression in acute Stanford type A dissection: a comparative microarray study.Irbesartan inhibits human T-lymphocyte activation through downregulation of activator protein-1.
P2860
Q24631725-A14827BF-CCE7-4816-9BDD-BCDC41AAD0D9Q24673267-43916083-1F76-4855-9816-010595FCB4BCQ24792943-63704789-18D3-4B0D-82A8-3466CFEC4674Q24816032-D75EEF40-B374-4371-B3E0-406B685EA0B6Q26779933-BBE4DD26-5D94-4614-863D-5265E8868EF0Q28281614-A7D50C07-E192-441B-B923-6EF6CEAFF5ECQ28346458-268613CF-D188-43E9-8D66-50EB6E556A02Q28565557-8DC7B58B-5112-4EE4-82E5-96C1D6C87A5FQ28610274-A5AF9F08-A3F1-4658-9888-1701CA0C9611Q30362092-8E3DDB5D-42A7-4343-A1CF-B8392E62C387Q30479528-9E892C16-713B-479A-A2B2-A20985862CF4Q30864901-854E0C53-2170-4DC4-9EDA-6680B70005AFQ33287995-0CC14F38-FF58-496F-A953-846A857B86A1Q33538129-47B2E514-F85E-4979-8588-A3EB98BB84AEQ33554938-254D1B8B-9CFF-47CB-B70A-21F1FFDCEA45Q33638905-756B634D-453A-4141-9F01-02D6F370C2FEQ33652126-3858AAEB-7354-4818-AAFC-C800A5E10524Q33692926-99F10D1C-EE7D-42F5-B213-DBD5723DAD36Q33843594-C77A72EC-AC5B-47BA-93B1-56376365E16FQ33883154-5CB57400-139B-46B7-AB53-D4BF0EB6AAE2Q33890391-964DABE6-74FE-4735-A7EF-9EF24E93BF82Q33909025-0A7D51BC-7685-468F-8D7A-1394FBBF5F8CQ34107334-041EFBBD-F66E-432E-8A7D-84981AF74371Q34107495-729A4DB8-C6F9-413F-9841-CDFE55BCABEAQ34289671-9E4EA651-B5DF-4983-86D6-97DED0BFCF8CQ34347211-8AAECA00-549C-4534-9B5E-4B8EDD2CED03Q34408250-C3F54412-BB78-4BDC-AE6B-40A02B723ABEQ34418975-DAF7B670-E43E-42AA-889D-60BD7E43F5ADQ34510788-CABCA4C0-06CE-410C-BDD0-C8BA2C6B80EBQ34586812-1760315D-65E5-476C-B543-44087DEC651EQ34624744-45456F1D-274F-44C8-8C7B-DBA8C62F78ABQ34655385-3C14E1EA-10D6-432E-ADE5-C9E9E3929F11Q34697950-F28B04BE-F482-4013-9738-645BCF4F17BCQ34705367-01D3F5F3-470F-4BAF-9C37-96867E2B4944Q34807187-2710732A-EB5A-45C1-9FBB-325A98587D1DQ34970381-806ABB12-B390-47DB-8246-0F83832E1187Q34981650-D7AC05CB-8746-454C-A932-9C444418087EQ35005859-03B2867D-37EA-4008-909C-C452245B8051Q35011911-037706C8-A4DE-4C40-8110-5ED4D7E81A66Q35047383-8685C07E-8A2E-4CD4-AD86-131DD975ABC3
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Matrix metalloproteinases and cardiovascular disease.
@en
type
label
Matrix metalloproteinases and cardiovascular disease.
@en
prefLabel
Matrix metalloproteinases and cardiovascular disease.
@en
P2093
P356
P1433
P1476
Matrix metalloproteinases and cardiovascular disease.
@en
P2093
P304
P356
10.1161/01.RES.77.5.863
P577
1995-11-01T00:00:00Z